

Jason R Guertin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8003574/publications.pdf>

Version: 2024-02-01

37
papers

356
citations

933447

10
h-index

888059

17
g-index

38
all docs

38
docs citations

38
times ranked

672
citing authors

#	ARTICLE	IF	CITATIONS
1	Health utilities in burn injury survivors: A systematic review. <i>Burns</i> , 2022, 48, 13-22.	1.9	6
2	Issue with Evaluating Costs Over Time in a Context of Medical Guideline Changes: An Example in Myocardial Infarction Care Based on a Longitudinal Study from 1997 to 2018. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 11-20.	1.9	0
3	Health-Related Quality of Life of Patients Presenting to the Emergency Department with a Musculoskeletal Disorder. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 91-103.	1.9	2
4	Economic Evaluation of In-Hospital Clinical Practices in Acute Injury Care: A Systematic Review. <i>Value in Health</i> , 2022, 25, 844-854.	0.3	3
5	The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context. <i>Current Oncology</i> , 2022, 29, 3393-3424.	2.2	4
6	A Value-Based Comparison of the Management of Ambulatory Respiratory Diseases in Walk-in Clinics, Primary Care Practices, and Emergency Departments: Protocol for a Multicenter Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e25619.	1.0	10
7	Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1-7.	1.4	3
8	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. <i>Cancers</i> , 2021, 13, 2729.	3.7	8
9	Evidence of the Different Associations of Prognostic Factors With Censoring Across Treatment Groups and Impact on Censoring Weight Model Specification: The Example of Anticoagulation in Atrial Fibrillation. <i>American Journal of Epidemiology</i> , 2021, 190, 2671-2679.	3.4	2
10	Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire. <i>Value in Health</i> , 2021, 24, 1172-1181.	0.3	8
11	Economic evaluation of intrahospital clinical practices in injury care: protocol for a 10-year systematic review. <i>BMJ Open</i> , 2020, 10, e034472.	1.9	1
12	A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017. <i>Medical Decision Making</i> , 2020, 40, 582-595.	2.4	5
13	Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey. <i>CMAJ Open</i> , 2020, 8, E41-E47.	2.4	2
14	Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. <i>BMJ Open</i> , 2019, 9, e028637.	1.9	6
15	Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey. <i>Cmaj</i> , 2018, 190, E155-E161.	2.0	38
16	A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 241-254.	3.8	12
17	Just how much does it cost? A cost study of chronic pain following cardiac surgery. <i>Journal of Pain Research</i> , 2018, Volume 11, 2741-2759.	2.0	11
18	Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 641-652.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 127-137.	1.9	16
20	Body-mass index and metastatic melanoma outcomes. <i>Lancet Oncology</i> , The, 2018, 19, e226.	10.7	2
21	Health Utilities Index Mark 3 scores for major chronic conditions: Population norms for Canada based on the 2013 and 2014 Canadian Community Health Survey. <i>Health Reports</i> , 2018, 29, 12-19.	0.8	30
22	The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. <i>Obesity Surgery</i> , 2017, 27, 349-356.	2.1	30
23	Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 95-105.	3.8	16
24	Senior high-cost healthcare users' resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. <i>BMJ Open</i> , 2017, 7, e018488.	1.9	6
25	Illustration of the Impact of Unmeasured Confounding Within an Economic Evaluation Based on Nonrandomized Data. <i>MDM Policy and Practice</i> , 2017, 2, 238146831769771.	0.9	2
26	Use of continuous exposure variables when examining dose-dependent pharmacological effects "Application to the association between exposure to higher statin doses and the incidence of diabetes. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2017, 24, 5-15.	1.9	4
27	Performance of the high-dimensional propensity score in adjusting for unmeasured confounders. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1497-1505.	1.9	33
28	Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population. <i>Current Medical Research and Opinion</i> , 2016, 32, 1955-1958.	1.9	0
29	Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 497.	1.9	4
30	Challenge of Informing Patient Decision Making: What Can We Tell Patients Considering Long-Term Mechanical Circulatory Support About Outcomes, Daily Life, and End-of-Life Issues?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 179-187.	2.2	14
31	Should Eligibility for Heart Transplantation Be a Requirement for Left Ventricular Assist Device Use? Recommendations Based on a Systematic Review. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1712-1720.	1.7	7
32	Atrial Fibrillation and Congestive Heart Failure: A Cost Analysis of Rhythm-Control vs Rate-Control Strategies. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1256-1262.	1.7	10
33	Transcatheter Aortic Valve Implantation: Recommendations for Practice Based on a Multidisciplinary Review Including Cost-Effectiveness and Ethical and Organizational Issues. <i>Canadian Journal of Cardiology</i> , 2013, 29, 718-726.	1.7	23
34	Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. <i>Journal of Medical Economics</i> , 2012, 15, 53-60.	2.1	21
35	Atrial Fibrillation: A Real-Life Observational Study in the Qu'bec Population. <i>Canadian Journal of Cardiology</i> , 2011, 27, 794-799.	1.7	5
36	Analysis of Willingness to Pay for Implantable Cardioverter-Defibrillator Therapy. <i>American Journal of Cardiology</i> , 2011, 107, 423-427.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Willingness To Pay To Eliminate the Risk of Restenosis Following Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 46-52.	2.2	5